Novel biallelic mutations in PADI6 in patients with early embryonic arrest

J Hum Genet. 2022 May;67(5):285-293. doi: 10.1038/s10038-021-00998-8. Epub 2022 Jan 6.

Abstract

Peptidyl arginine deiminase, type VI (PADI6) is a member of the subcortical maternal complex (SCMC), which plays vital roles in mammalian embryogenesis. Most mutations in SCMC members have been reported to cause human embryonic arrest, and a total of 15 mutations in PADI6 have been shown to be responsible for early embryonic arrest according to previous studies. However, the genetic factors behind this phenotype remain to be understood in further detail. Here, we identified 13 novel mutations and 4 previously reported mutations of PADI6 in 14 patients who were diagnosed with abnormal embryonic development caused by early arrest, embryonic fragmentation, and recurrent implantation failure. Most of the mutations were predicted by in silico analysis to be deleterious or damaging to the function of PADI6. In addition, the total and East Asian population frequencies of the mutations were low or absent in the gnomAD database. Our study expands the mutational spectrum in PADI6 and will provide precise targets for genetic counseling in the future.

MeSH terms

  • Animals
  • Embryonic Development
  • Female
  • Humans
  • Mammals*
  • Mutation
  • Oocytes*
  • Phenotype
  • Pregnancy
  • Protein-Arginine Deiminase Type 6

Substances

  • PADI6 protein, human
  • Protein-Arginine Deiminase Type 6